Condition · ICD-11 2A00
Cancer-related symptoms
Reviewed by Dr. Placeholder E (HPCSA MP0XXXXX · Palliative Care) · Last updated · Published
Cancer-related symptoms — pain, chemotherapy-induced nausea and vomiting, appetite loss, cachexia — are commonly managed alongside oncology treatment and palliative care. Cannabinoids have a long-standing role as adjunctive symptom management in this population, particularly in patients where conventional antiemetics or analgesics have been inadequate. Critically: cannabinoids are **not** treatments for cancer itself. They are evaluated only as supportive care, coordinated with the oncology team, and never positioned as anti-tumour therapy.
What the evidence says
Smith et al (2015 Cochrane) reviewed cannabinoids for chemotherapy-induced nausea and vomiting and found modest efficacy, with older agents (nabilone, dronabinol) having the most data. NCCN palliative-care guidelines recognise cannabinoids as a reasonable option in refractory CINV after first-line 5-HT3 antagonists. For cancer pain, cannabinoids are an adjunct rather than a replacement for opioid analgesics; data are mixed but supportive in palliative populations. The framing in South Africa is explicitly symptomatic, not therapeutic against the tumour.
How the doctor will evaluate you
The doctor will require your oncology team’s current treatment plan, a list of prior antiemetics with response, a clear pain history, and any palliative-care team involvement. Coordination with your oncologist is expected — Docto24’s panel does not initiate cannabinoid therapy in active oncology patients without oncology-team awareness. Both THC and CBD formulations may be appropriate depending on which symptoms dominate.
When to see a doctor urgently
- No oncology team involvement — we cannot responsibly proceed without their awareness
- Acute clinical instability (sepsis, uncontrolled pain, bowel obstruction) — in-person care needed
- Claims that cannabinoids will treat or cure cancer — we do not support that framing
- Interactions with chemotherapy agents — requires oncology-pharmacy review
If any of the above apply, seek in-person medical care — do not wait for a remote Section 21 consultation.
The South African Section 21 pathway
Cancer-symptom cases are routinely reviewed in SA’s Section 21 pathway where conventional antiemetics or analgesics have been insufficient. Applications carry extra weight when coordinated with the oncology team and aligned with the patient’s palliative-care plan. Authorisations are time-limited and regularly re-evaluated as treatment progresses.
Frequently asked
- Can medical cannabis cure cancer?
- No. There is no credible clinical evidence that cannabinoids cure or reverse cancer. They are used as adjunctive symptom management — for pain, nausea, appetite loss — alongside evidence-based oncology care. Claims otherwise are unsafe and not supported by Docto24 or its doctor panel.
- Will this interact with my chemotherapy?
- Potentially. Several cytotoxic agents interact with CYP450 pathways that cannabinoids also affect. The doctor will discuss this with your oncology team and flag any regimens where the interaction risk outweighs the symptomatic benefit.
- Is cannabinoid therapy instead of my current pain medication?
- Almost never. In active oncology pain, cannabinoids are adjunctive. The focus is on managing total symptom burden — not on replacing opioids, which often remain clinically necessary.
Related conditions
Think this might apply to you? An HPCSA-registered doctor will review your case.
START ELIGIBILITY REVIEWR500 consultation · R400 SAHPRA fee per product · 3–7 days end-to-end